ClinicalTrials.gg

Program

RNK08954

A development code. Also written as “IN10018 in combination with RNK08954”.

Its studies are led by 3 companies.

Furthest: phase 2, since Nov 30, 20254 company-led studies, 4 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ranok Therapeutics (Hangzhou)22 open or runningphase 2since Nov 30, 2025Nov 30, 2025Nov 30, 2026phase 2 · NCT07303465
InxMed (Shanghai)11 open or runningphase 2since Feb 13, 2026Feb 13, 2026Feb 28, 2031phase 2 · NCT07441174
Ranok Therapuetics11 open or runningphase 2since Aug 31, 2026Aug 31, 2026Aug 31, 2028phase 2 · NCT07848893

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 30, 2025First study: phase 2 study in KRAS G12D MutationsNew to Ranok Therapeutics (Hangzhou)Ranok Therapeutics (Hangzhou) · NCT07303465 · 60 planned · China
  2. Dec 31, 2025Phase 1 study in Food EffectRanok Therapeutics (Hangzhou) · NCT07334262 · 24 planned · China
  3. Feb 13, 2026InxMed (Shanghai)'s first study: phase 2 study in Solid Tumor CancerNew to InxMed (Shanghai)InxMed (Shanghai) · NCT07441174 · 92 planned · China
  4. Aug 31, 2026Ranok Therapuetics's first study: phase 2 study in Advanced Gynecologic MalignanciesNew to Ranok TherapueticsRanok Therapuetics · NCT07848893 · 120 planned · China

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in KRAS G12D MutationsRanok Therapeutics (Hangzhou) · NCT07303465
  2. Dec 1, 2026Primary completion: phase 1 study in Food EffectRanok Therapeutics (Hangzhou) · NCT07334262
  3. Aug 31, 2028Primary completion: phase 2 study in Advanced Gynecologic MalignanciesRanok Therapuetics · NCT07848893
  4. Feb 28, 2031Primary completion: phase 2 study in Solid Tumor CancerInxMed (Shanghai) · NCT07441174

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07848893Advanced Gynecologic Malignancies · China2Not yet recruitingRanok TherapueticsAug 31, 2028120
NCT07441174Solid Tumor Cancer · China2RecruitingInxMed (Shanghai)Feb 28, 203192
NCT07334262Food Effect · China1Not yet recruitingRanok Therapeutics (Hangzhou)Dec 1, 202624
NCT07303465KRAS G12D Mutations · China2RecruitingRanok Therapeutics (Hangzhou)Nov 30, 202660

How it is read

Names in the registry

  • “RNK08954”, 3 entries
  • “IN10018 in combination with RNK08954”, 1 entry

Codes read as this program: RNK08954.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.